- DEA Officially Deschedules GW Pharma’s CBD Epilepsy Treatment Epidiolex
- it has obtained a notice from the Drug Enforcement Administration certifying that its Epidiolex oral solution has been descheduled and is no longer a controlled substance.
- This notification from DEA fully establishes that EPIDIOLEX, the only CBD medicine approved by FDA, is no longer a controlled substance under the federal Controlled Substances Act, GW Pharma CEO Justin Gover said in a statement.
- After obtaining the DEA notice, the Cambridge, U.K.-based company said it has filed a post-approval supplement with the FDA to lift the Schedule V designation from the drug.
Read full article: greenentrepreneur.com